$SANA News

Last published 6d ago

6d agoSANASana Biotechnology, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
6d agoSANASana Biotechnology Reports Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswireContinued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on publication in The New England
2mo agoAVAI VRTX SANAReplacing Insulin Cells Works. Keeping The Cells Alive Is the TrickGlobeNewswireIssued on behalf of AVAI Bio, Inc. LAS VEGAS, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - Type 1 diabetes has an unusual property among serious diseases: the science of curing it is largely
2mo agoSANASana Biotechnology to Present at September 2026 Investor ConferencesGlobeNewswireSEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its
3mo agoSANASana Biotechnology Reports Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswireContinued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical
4mo agoSANASana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 DiabetesGlobeNewswirePeer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025 Seminal Study Successfully Achieved Primary and Secondary
4mo agoSANA ELDN NCEL VRTXThe Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho TherapyPR NewswireUSA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the...
4mo agoSANASana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026GlobeNewswireSEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation
5mo agoSANADid Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR Newswirealper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Sana Biotechnology, Inc. (NASDAQ: SANA)...
5mo agoVRTX ALNY BEAM SANAAnti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain MomentumPR NewswireCell and gene therapy has crossed a meaningful inflection in 2026. Vertex Pharmaceuticals reported Q1 product revenue of $2.99 billion, with newer...
5mo agoSANASana Biotechnology to Present at June 2026 Investor ConferencesGlobeNewswireSEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations
6mo agoSANASana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) FacilityGlobeNewswireSEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of
6mo agoSANASana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsGlobeNewswireSEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data
6mo agoSANASana Biotechnology Reports First Quarter 2026 Financial Results and Business UpdatesGlobeNewswireAnnounced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later this year, including
6mo agoSANASana Biotechnology to Present at the BofA Securities 2026 Healthcare ConferenceGlobeNewswireSEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation
6mo agoSANASana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual MeetingGlobeNewswireSEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting
7mo agoSANASana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451GlobeNewswireSana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients with type 1 diabetes Initial efforts will include processes
7mo agoVCEL SANA LCTX ELDNWhy Smart Money Is Shifting From Clinical Data to Manufacturing LinesPR NewswireThe global cell therapy manufacturing market is on track to nearly double, from $7.17 billion in 2026 to over $14 billion by 2035[1]. The science has ...
8mo agoSANASana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without ImmunosuppressionGlobeNewswireGroundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression 14-Month Follow-up Data Show Hypoimmune (HIP)-Modified Islets are
8mo agoSANASana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesGlobeNewswireShared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the
8mo agoSANASana Biotechnology to Present at March 2026 Investor ConferencesGlobeNewswireSEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its
8mo agoSANASana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial OfficerGlobeNewswireSEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as
10mo agoSANASana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation
11mo agoSANASana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen PlatformGlobeNewswireData Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology Broadens Application of Fusogen Technology
11mo agoSANASana Biotechnology to Present at December 2025 Investor ConferencesGlobeNewswireSEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its
11mo agoAVAI CRSP SANAThe Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease CareGlobeNewswireIssued on behalf of Avant Technologies Inc. VANCOUVER, British Columbia, Nov. 19, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – The autologous cell therapy market surpassed $10.1 billion in 2025 as
1y agoSANASana Biotechnology Reports Third Quarter 2025 Financial Results and Business UpdatesGlobeNewswireAnnounced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan, and path to filing
1y agoSANASana Biotechnology to Present at the TD Cowen Immunology & Inflammation SummitGlobeNewswireSEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation
1y agoSANASana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
1y agoSANASana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
1y agoSANASana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
1y agoIQV FHTX MRNA SANAIQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences CompaniesPR NewswireIQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, ...
1y agoSANASana Biotechnology to Present at September 2025 Investor ConferencesGlobeNewswireSEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its
1y agoSANASana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA) ("Sana"), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale
1y agoSANASana Biotechnology Reports Second Quarter 2025 Financial Results and Business UpdatesGlobeNewswirePresented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to
1y agoFHTX MRNA SANAAjit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship PioneeringPR NewswireFlagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer,...
1y agoSANASana Biotechnology Announces Pricing of Public OfferingGlobeNewswireSEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA) ("Sana"), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its
1y agoSANASana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA) ("Sana"), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an
1y agoMCRB SANASeres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireFollowing FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat
1y agoSANASana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 DiabetesGlobeNewswireData Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to
1y agoFHTX MRNA SANAFlagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology PlatformPR NewswireFlagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions...
1y agoSANASana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific SessionsGlobeNewswireSEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation
1y agoSANASana Biotechnology to Present at June 2025 Investor ConferencesGlobeNewswireSEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations
1y agoSANASana Biotechnology, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANAPR Newswirehe Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA...
1y agoSANASANA Investors Have the Opportunity to Lead the Sana Biotechnology Securities Fraud Lawsuit with Faruqi & Faruqi, LLPGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sana To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
1y agoSANAInvestors in Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA...
1y agoSANAINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana BiotechnologyGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options If you suffered losses
1y agoSANASana Biotechnology to Present at the BofA Securities 2025 Healthcare ConferenceGlobeNewswireSEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation
1y agoFHTX MRNA SANATed Myles Joins Cellarity as Chief Executive OfficerPR NewswireCellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today...
1y agoSANASana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANAPR NewswireThe Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA...